{
    "clinical_study": {
        "@rank": "161468", 
        "arm_group": [
            {
                "arm_group_label": "Varying amounts of Beneprotein", 
                "arm_group_type": "Experimental", 
                "description": "1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day"
            }, 
            {
                "arm_group_label": "1 Gram - Standard Therapy given in ICU", 
                "arm_group_type": "Active Comparator", 
                "description": "1 gram/kg/day of protein"
            }
        ], 
        "brief_summary": {
            "textblock": "It is well accepted that during critical illness there is an increase in protein breakdown\n      and loss of lean body mass. Previous studies have shown that during critical illness muscle\n      breakdown increases dramatically. The aim of our study is to test the hypothesis that\n      critically ill patients have improved outcomes with higher protein supplementation."
        }, 
        "brief_title": "Optimal Protein Supplementation for Critically Ill Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Critical Illness", 
        "condition_browse": {
            "mesh_term": "Critical Illness"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Medical or surgical patients who are admitted or transferred to the ICU with an\n             APACHE II score greater than or equal to 18 and who are candidates for enteral\n             nutrition within 48 hours of admission.\n\n        Exclusion Criteria:\n\n          -  \u2022 Patients who cannot tolerate enteral nutrition\n\n               -  Patients who have a contraindication for enteral nutrition per American Society\n                  of Enteral and Parenteral Nutrition guidelines (GI obstruction, intractable\n                  nausea and/or vomiting, short bowel syndrome, distal GI fistula, GI bleeding\n                  that will require endoscopy, malabsorption that requires TPN, inability to\n                  access the GI tract\n\n               -  Patients with chronic stage III or IV kidney disease and/or patients  receiving\n                  dialysis within six months of this hospital admission as these patients are\n                  known to require specific  protein diets as an outpatient.  Patients with acute\n                  kidney injury will not be excluded as there is no evidence to suggest these\n                  patients require a specific protein diet secondary to their acute kidney injury.\n\n               -  Patients with refractory hypotension unresponsive to vasoactive medications\n\n               -  Patients who are unlikely to survive the next 48 hours at the time of enrollment\n                  (this will be judged by the treating physician)\n\n               -  Patients who are unable to give consent and do not have a family member able to\n                  give consent on his/her behalf.\n\n               -  Patients with end stage liver disease or undergoing liver transplant or liver\n                  resection surgery\n\n               -  Patients whose physician thinks he/she should not participate\n\n               -  Prisoners\n\n               -  Pregnant women (all female of childbearing age will have a urine pregnancy test\n                  prior to randomization)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934595", 
            "org_study_id": "3440", 
            "secondary_id": "SCCM Vision"
        }, 
        "intervention": {
            "arm_group_label": [
                "Varying amounts of Beneprotein", 
                "1 Gram - Standard Therapy given in ICU"
            ], 
            "description": "The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.", 
            "intervention_name": "Beneprotein", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Critically ill", 
            "Protein", 
            "Supplement", 
            "ICU", 
            "Protein synthesis"
        ], 
        "lastchanged_date": "September 13, 2013", 
        "location": {
            "contact": {
                "last_name": "Gary T. Kinasewitz, MD", 
                "phone": "405-271-6173"
            }, 
            "contact_backup": {
                "email": "ashley-ellis@ouhsc.edu", 
                "last_name": "Ashley L Ellis, RN", 
                "phone": "405-271-6173"
            }, 
            "facility": {
                "address": {
                    "city": "Oklahoma City", 
                    "country": "United States", 
                    "state": "Oklahoma", 
                    "zip": "73104"
                }, 
                "name": "OUHSC"
            }, 
            "investigator": [
                {
                    "last_name": "Gary T. Kinasewitz, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Karen Allen, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Optimal Protein Supplementation for Critically Ill Patients", 
        "other_outcome": [
            {
                "measure": "Number of days in ICU", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Infection Rate", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Discharge location", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "New or Significantly worsening skin breakdown", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Mechanical Vent free days", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "overall_contact": {
            "last_name": "Gary T Kinasewitz, MD", 
            "phone": "405-271-6173"
        }, 
        "overall_contact_backup": {
            "email": "ashley-ellis@ouhsc.edu", 
            "last_name": "Ashley L Ellis, RN", 
            "phone": "405-271-6173"
        }, 
        "overall_official": {
            "affiliation": "OUHSC", 
            "last_name": "Gary T. Kinasewitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome will be cumulative organ failure free days (defined as no aggressive medical support for the patient's vital organ systems; including cardiovascular, respiratory, renal, bone marrow, and liver.", 
            "measure": "Cumulative Organ failure free days", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934595"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Mortality", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "source": "University of Oklahoma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Oklahoma", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}